271 related articles for article (PubMed ID: 24683059)
1. Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.
Meyer Dos Santos S; Harder S
Drug Saf; 2014 May; 37(5):295-307. PubMed ID: 24683059
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
Brunetti L; Chen C; White J
Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
[TBL] [Abstract][Full Text] [Related]
3. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
Salazar CA; del Aguila D; Cordova EG
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
[TBL] [Abstract][Full Text] [Related]
5. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
[TBL] [Abstract][Full Text] [Related]
6. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
Chevalier J; Giroud M; de Pouvourville G
Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
[TBL] [Abstract][Full Text] [Related]
8. [Expectation to and problems of thrombin inhibitor].
Uchiyama S
Rinsho Shinkeigaku; 2011 Nov; 51(11):1004-6. PubMed ID: 22277458
[TBL] [Abstract][Full Text] [Related]
9. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran.
Barrios V; Escobar C
Expert Opin Pharmacother; 2012 Dec; 13(18):2649-61. PubMed ID: 23167273
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
Waks JW; Zimetbaum PJ
Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Bendel SD; Bona R; Baker WL
Adv Ther; 2011 Jun; 28(6):460-72. PubMed ID: 21533567
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong.
Ho JC; Chang AM; Yan BP; Yu CM; Lam YY; Lee VW
Clin Cardiol; 2012 Dec; 35(12):E40-5. PubMed ID: 23108916
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
Ferreira J; Ezekowitz MD; Connolly SJ; Brueckmann M; Fraessdorf M; Reilly PA; Yusuf S; Wallentin L;
Eur J Heart Fail; 2013 Sep; 15(9):1053-61. PubMed ID: 23843099
[TBL] [Abstract][Full Text] [Related]
15. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
[TBL] [Abstract][Full Text] [Related]
16. Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Weimar C; Hohnloser SH; Eikelboom JW; Diener HC
Curr Neurol Neurosci Rep; 2012 Feb; 12(1):17-23. PubMed ID: 21960064
[TBL] [Abstract][Full Text] [Related]
17. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ
Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
20. [Direct oral thrombin inhibitor, "dabigatran"].
Yasaka M
Nihon Rinsho; 2013 Jan; 71(1):113-8. PubMed ID: 23631181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
